Melanoma patients frequently lack the knowledge or confidence to perform regular, effective skin self-exams (SSEs), according to recent research.
Studies point to a frequent disconnect between the priorities of clinical investigators and patient and physician end users. Engaging patients and other stakeholders in research prioritization can enhance study relevance and may even shorten the time it takes to bring scientific discoveries from the laboratory to the bedside.
A newer class of medications that enables the immune system to identify and attack diseased cells is transforming the way clinicians fight advanced melanoma. At the head of that charge is the drug pembrolizumab.
The synergies created by the joining of Lancaster General Health and the University of Pennsylvania Health System (Penn Medicine) enable providers throughout the system to work in an environment of close collaboration that benefits patients and physicians alike.
Penn State Health is shaping the future of medicine both regionally and globally by pushing the boundaries of clinical care, research, education and community health.
- 1 of 7
- next ›